The effect of therapies for osteoporosis on spine fusion: a systematic review.
BACKGROUND
Fusion of the spine requires de novo bone formation and remodeling, processes that rely heavily on the action of the osteoblast and osteoclast. Bisphosphonate drugs and intermittent parathyroid hormone (PTH) therapy are widely prescribed to treat osteoporosis and act on the osteoblast/osteoclast complex. The impact of these medications on spine fusion is not known.


OBJECTIVE
To evaluate the available evidence on the potential impact of bisphosphonates and PTH on fusion rate and fusion quality in spinal arthrodesis.


METHODS
A systematic review of the literature.


METHODS
All available literature regarding the impact of bisphosphonates and PTH on spinal fusion.


METHODS
Fusion rate and histologic, microstructural, or biomechanical measures of fusion quality.


METHODS
A systematic review of the literature published between 1980 and 2011 was conducted using major electronic databases. The results of studies meeting criteria for inclusion were then aggregated and examined for consensus on the effect of these medications on spine fusion.


RESULTS
The literature contained 18 animal studies and one clinical trial investigating the impact of these medications on spine fusion. Most animal studies evaluating the impact of bisphosphonates on fusion rate have not found statistically significant changes with treatment, although this fact may be attributable to low statistical power. The animal literature does suggest that bisphosphonate therapy results in a less histologically mature fusion mass; however, the impact of these changes on fusion mass biomechanics is unclear. The only available human study suggests that these bisphosphonates may increase the radiographically defined fusion rate but did not demonstrate an impact on clinical outcome. In animals, PTH improves the fusion rate and fusion mass microstructure, but data on its effect on fusion mass biomechanics are lacking. No studies have evaluated the impact of PTH on spine fusion in humans.


CONCLUSIONS
In animals, bisphosphonate therapy appears to impede maturation of the fusion mass, with an unclear effect on mechanical strength. This effect was not seen in the lone human study, which suggested that these medications improved the radiographically defined fusion rate. The available animal studies on intermittent PTH treatment suggest that it may improve fusion rate and fusion mass microstructure. Given the widespread use of these agents, further investigation into their impact on human spine fusion is necessary to inform the care of patients with osteoporosis who are undergoing spine surgery.
Department of Orthopaedic Surgery, University of Miami/Jackson Health System, PO Box 016960 (D-27), Miami, FL 33101, USA. bhirsch@med.miami.edu
Brandon P
BP
Hirsch
Aasis
A
Unnanuntana
Matthew E
ME
Cunningham
Joseph M
JM
Lane
D000818:Animals; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016025:Bone Transplantation; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008159:Lumbar Vertebrae / Q000187:drug effects* / Q000601:surgery; D010012:Osteogenesis / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy* / Q000601:surgery; D013123:Spinal Fusion / Q000379:methods*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates